Irritable bowel syndrome: modern aspects of diagnosis and treatment
Abstract
Functional bowel diseases, in particular irritable bowel syndrome (IBS), are not sometimes taken seriously by many general practitioners. However, high incidence of IBS, the associated therapeutic challenges and a significant life quality deterioration make it a relevant issue.
References
1. Tornblom H, Holmvall P, Svenungsson B, Lindberg G. Gastrointestinal symptoms after infections diarrhea: a five -year follow up in a swedish cohort of adults. Clin Gastroenterol Hepatol, 2007, 5: 461-464.
2. Парфенов А.И., Ручкина И.Н., Атуллаханов РИ. и др. Постинфекционный синдром раздраженной кишки. Терапевтический архив, 2009, 81 (2): 39-45.
3. Маев И.В., Черемушкин С.В. Психосоциальные факторы в развитии синдрома раздраженной кишечника, возможности терапии. Consilium medicum, 2006, 7: 34-42.
4. Яковенко Э.П., Агафонова Н.А., Яковенко А.В. и др. Роль моторных нарушений в механизмах формирования клинических проявлений синдрома раздраженной кишки (СРК) и СРК-подобных нарушений. Вопросы терапии. Consilium Medicum, 2011, 1: 69-73.
5. Drossman DA. Treatment for bacterial overgrowth in the irritable bowel syndrome. An Intern Med, 2006, 145: 626843.
6. Farrokhyar F, Marshall JK, Easterbrook B. et al. Functional Gastrointestinal Disorders and Mood Disorders in Patients with Inactive Inflammatory Bowel Disease: Prevalence and Impact on Health. Inflam BowelDis, 2006, 12(1): 38-45.
7. Levels of Evidence. Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawes since November 1998. Updated by Jeremy Howick March 2009. Oxford Centre for Evidence-based Medicine, 2009.
8. Приказ Минздрава России от 24 декабря 2012 г. № 1420н «Об утверждении стандарта специализированной медицинской помощи при синдроме раздраженного кишечника (без диареи)».
9. Приказ Минздрава России от 9 ноября 2012 г. № 774н «Об утверждении стандарта специализированной медицинской помощи при синдроме раздраженного кишечника (с диареей)».
10. Ruepert et al. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. The Cochrane Collaboration. The Cochrane Library, 2013, 3.
11. Schang et al. Effects of trimebutine on colonic function in patients with chronic idiopathic constipation: evidence for the need of a physiologic rather than clinical selection. Dis Colon Rectum., 1993, Apr, 36(4): 330-6.
12. Zhong et al. A randomized and case-control clinical study on trimebutine maleate in treating functional dyspepsia coexisting with diarrhea-dominant irritable bowel syndrome. Zhonghua Nei Ke Za Zhi, 2007, Nov, 46(11): 899-902.
13. Luttecke et al. A trial of trimebutine in spastic colon. Journal of International Medical Research, 1978, 6: 86-88.
14. Schaffstein W, Panijel M, Luttecke K. Comparative safety and efficacy of trimebutine versus mebeverine in the treatment of irritable bowel syndrome. A multicenter double-blind study. Current Therapeutic Research, Clinical and Experimental, 1990, 47(1): 136-45.
15. Roman FJ, Lanet S, Hamon J et al. Pharmacological properties of trimebutine and N-monodesmethyltrimebutine. J Pharmacol Exp Ther., 1999, 289 (3): 1391-1397.
Review
For citations:
Vasilyev YV. Irritable bowel syndrome: modern aspects of diagnosis and treatment. Meditsinskiy sovet = Medical Council. 2014;(4):72-77. (In Russ.)
Views:
541
Email this article 